On May 25, 2021, GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced that the highly-regarded journal Nature Medicine has published the first case report of partial recovery of visual function in a blind patient with late-stage retinitis pigmentosa (RP). The subject is a participant in the ongoing PIONEER Phase I/II clinical trial of GenSight Biologics’ GS030 optogenetic therapy. Published online on May 24, 2021, under the title “Partial Recovery of Visual Function in a Blind Patient After Optogenetic Therapy,” the open-access paper is the first peer-reviewed documentation of visual recovery after a blind patient was treated with optogenetic therapy. “These are truly groundbreaking findings that move the promise of optogenetics another step from therapeutic concept to clinical use,” commented Bernard Gilly, PhD, Co-Founder and Chief Executive Officer of GenSight.
Login Or Register To Read Full Story